CM
ABBV icon

Capula Management’s AbbVie ABBV Stock Holding History

Capula Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.07M Buy
4,900
+1,200
+32% +$266K 0.01% 354
2025
Q4 		$845K Sell
3,700
-3,000
-45% -$683K ﹤0.01% 313
2025
Q3 		$1.55M Buy
6,700
+4,700
+235% +$957K 0.01% 294
2025
Q2 		$371K Sell
2,000
-1,300
-39% -$242K ﹤0.01% 266
2025
Q1 		$691K Buy
+3,300
New +$642K ﹤0.01% 287
2024
Q4 		– Sell
-2,500
Closed -$494K – 365
2024
Q3 		$494K Sell
2,500
-2,600
-51% -$485K 0.01% 249
2024
Q2 		$875K Buy
+5,100
New +$845K 0.01% 171
2023
Q4 		– Sell
-6,200
Closed -$924K – 290
2023
Q3 		$924K Sell
6,200
-136,500
-96% -$20M 0.02% 231
2023
Q2 		$19.2M Sell
142,700
-62,300
-30% -$9.14M 0.47% 35
2023
Q1 		$32.7M Buy
205,000
+48,600
+31% +$7.43M 0.39% 51
2022
Q4 		$25.3M Buy
156,400
+35,400
+29% +$5.43M 0.34% 78
2022
Q3 		$16.2M Sell
121,000
-753,500
-86% -$108M 0.22% 123
2022
Q2 		$134M Buy
874,500
+822,500
+1,582% +$126M 2.29% 5
2022
Q1 		$8.43M Buy
+52,000
New +$7.55M 0.12% 149
2021
Q4 		– Sell
-56,100
Closed -$5.98M – 170
2021
Q3 		$5.98M Buy
56,100
+36,100
+181% +$4.12M 0.07% 209
2021
Q2 		$2.23M Sell
20,000
-50,400
-72% -$5.68M 0.04% 283
2021
Q1 		$7.62M Buy
70,400
+44,100
+168% +$4.72M 0.15% 157
2020
Q4 		$2.82M Buy
+26,300
New +$2.53M 0.14% 139
2020
Q3 		– Sell
-155,000
Closed -$15.2M – 134
2020
Q2 		$15.2M Buy
155,000
+80,000
+107% +$7.04M 0.54% 40
2020
Q1 		$5.71M Buy
75,000
+50,000
+200% +$4.26M 0.21% 144
2019
Q4 		$2.21M Sell
25,000
-112,900
-82% -$9.37M 0.05% 246
2019
Q3 		$10.4M Buy
+137,900
New +$9.45M 0.22% 105

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capula Management's ABBV Position: Q1 2026 in Review

Capula Management increased its AbbVie (ABBV) stake by 315% in Q1 2026, buying an estimated $1.08M and bringing the position to 6,392 shares worth $1.39M. The position accounts for 0.01% of the portfolio, ranked #308.

Capula Management first reported a position in ABBV in Q2 2019 and has held it in 18 quarters since. The position peaked at $7.03M in Q1 2020. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Capula Management held 6,392 shares of AbbVie worth $1.39M as of Q1 2026.
  • Capula Management bought 4,852 AbbVie shares in Q1 2026, an estimated $1.08M.
  • AbbVie made up 0.01% of Capula Management's portfolio in Q1 2026, its #308 holding.
  • Capula Management first reported a position in AbbVie in Q2 2019 and has held it in 18 quarters since.
  • Capula Management's AbbVie position peaked at $7.03M in Q1 2020.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Capula Management's 13F filing for Q1 2026, filed 14 May 2026.